197 related articles for article (PubMed ID: 28231806)
1. Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma.
Burmakin M; van Wieringen T; Olsson PO; Stuhr L; Åhgren A; Heldin CH; Reed RK; Rubin K; Hellberg C
J Transl Med; 2017 Feb; 15(1):47. PubMed ID: 28231806
[TBL] [Abstract][Full Text] [Related]
2. The Tyrosine Kinase Inhibitor Imatinib Augments Extracellular Fluid Exchange and Reduces Average Collagen Fibril Diameter in Experimental Carcinoma.
Olsson PO; Gustafsson R; In 't Zandt R; Friman T; Maccarana M; Tykesson E; Oldberg Å; Rubin K; Kalamajski S
Mol Cancer Ther; 2016 Oct; 15(10):2455-2464. PubMed ID: 27474147
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of integrin α
Olof Olsson P; Gustafsson R; Salnikov AV; Göthe M; Zeller KS; Friman T; Baldetorp B; Koopman LA; Weinreb PH; Violette SM; Kalamajski S; Heldin NE; Rubin K
Cell Commun Signal; 2018 Jul; 16(1):36. PubMed ID: 29966518
[TBL] [Abstract][Full Text] [Related]
4. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
Vlahovic G; Rabbani ZN; Herndon JE; Dewhirst MW; Vujaskovic Z
Br J Cancer; 2006 Oct; 95(8):1013-9. PubMed ID: 17003785
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.
Pietras K; Ostman A; Sjöquist M; Buchdunger E; Reed RK; Heldin CH; Rubin K
Cancer Res; 2001 Apr; 61(7):2929-34. PubMed ID: 11306470
[TBL] [Abstract][Full Text] [Related]
6. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma.
Kłosowska-Wardega A; Hasumi Y; Burmakin M; Ahgren A; Stuhr L; Moen I; Reed RK; Rubin K; Hellberg C; Heldin CH
PLoS One; 2009 Dec; 4(12):e8149. PubMed ID: 19997591
[TBL] [Abstract][Full Text] [Related]
7. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.
Schiffmann LM; Brunold M; Liwschitz M; Goede V; Loges S; Wroblewski M; Quaas A; Alakus H; Stippel D; Bruns CJ; Hallek M; Kashkar H; Hacker UT; Coutelle O
Br J Cancer; 2017 Feb; 116(5):600-608. PubMed ID: 28141797
[TBL] [Abstract][Full Text] [Related]
8. Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors.
Boucher Y; Lee I; Jain RK
Microvasc Res; 1995 Sep; 50(2):175-82. PubMed ID: 8538498
[TBL] [Abstract][Full Text] [Related]
9. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.
Kitadai Y; Sasaki T; Kuwai T; Nakamura T; Bucana CD; Fidler IJ
Am J Pathol; 2006 Dec; 169(6):2054-65. PubMed ID: 17148668
[TBL] [Abstract][Full Text] [Related]
10. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
Ogawa Y; Kawamura T; Furuhashi M; Tsukamoto K; Shimada S
J Dermatol Sci; 2008 Sep; 51(3):190-9. PubMed ID: 18485676
[TBL] [Abstract][Full Text] [Related]
11. The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin.
Fan Y; Du W; He B; Fu F; Yuan L; Wu H; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2013 Mar; 34(9):2277-88. PubMed ID: 23290525
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
13. In silico investigations of intratumoral heterogeneous interstitial fluid pressure.
Waldeland JO; Gaustad JV; Rofstad EK; Evje S
J Theor Biol; 2021 Oct; 526():110787. PubMed ID: 34087266
[TBL] [Abstract][Full Text] [Related]
14. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).
Moawad EY
J Gastrointest Cancer; 2015 Sep; 46(3):272-83. PubMed ID: 25985771
[TBL] [Abstract][Full Text] [Related]
15. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications.
Griffon-Etienne G; Boucher Y; Brekken C; Suit HD; Jain RK
Cancer Res; 1999 Aug; 59(15):3776-82. PubMed ID: 10446995
[TBL] [Abstract][Full Text] [Related]
16. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
[TBL] [Abstract][Full Text] [Related]
17. Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma.
Lammerts E; Roswall P; Sundberg C; Gotwals PJ; Koteliansky VE; Reed RK; Heldin NE; Rubin K
Int J Cancer; 2002 Dec; 102(5):453-62. PubMed ID: 12432546
[TBL] [Abstract][Full Text] [Related]
18. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
Shinagawa K; Kitadai Y; Tanaka M; Sumida T; Onoyama M; Ohnishi M; Ohara E; Higashi Y; Tanaka S; Yasui W; Chayama K
Int J Cancer; 2013 Feb; 132(4):813-23. PubMed ID: 22821812
[TBL] [Abstract][Full Text] [Related]
19. Fibromodulin deficiency reduces collagen structural network but not glycosaminoglycan content in a syngeneic model of colon carcinoma.
Olsson PO; Kalamajski S; Maccarana M; Oldberg Å; Rubin K
PLoS One; 2017; 12(8):e0182973. PubMed ID: 28827814
[TBL] [Abstract][Full Text] [Related]
20. Morphology/Interstitial Fluid Pressure-Tunable Nanopomegranate Designed by Alteration of Membrane Fluidity under Tumor Enzyme and PEGylation.
Wu C; Wang Z; Wang X; Zou J; Wu Z; Liu J; Zhang W
Mol Pharm; 2021 May; 18(5):2039-2052. PubMed ID: 33769816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
